Guanadrel: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
 
m (Protected "Guanadrel": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{chembox
{{chembox new
| Verifiedfields = changed
| Verifiedfields = changed
| Watchedfields = changed
| Watchedfields = changed
Line 5: Line 5:
| UNII = 765C9332T4
| UNII = 765C9332T4
| verifiedrevid = 407386127
| verifiedrevid = 407386127
|ImageFile=Guanadrel.png
|ImageFile=Guanadrel Wiki str.png
|ImageSize=
|ImageSize=
|IUPACName=2-(1,4-Dioxaspiro[4.5]decan-2-ylmethyl)guanidine
|IUPACName=2-(1,4-Dioxaspiro[4.5]decan-2-ylmethyl)guanidine
Line 49: Line 49:
}}
}}
__NOTOC__
__NOTOC__
{{SI}}
{{CMG}}
{{CMG}}
==Overview==
==Overview==


Line 62: Line 62:
==Chemistry==
==Chemistry==
Guanadrel can be synthesized when [[cyclohexanone]] undergoes ketalization by 3-chloro-1,2-propanediol, forming 2-chloromethyl-1,4-dioxyspiro[4,5]decane, which is further reacted with sodium phthalimide.<ref>W.R. Hardie, J.E. Aaron, {{Cite patent|FR|1522153}} (1968)</ref><ref>W.R. Hardie, J.E. Aaron, S. Afr. Pat. 67 06.328 (1968)</ref><ref>J.E. Aaron, W.R. Hardie, {{US Patent|3547951}} (1970)</ref> After alkaline hydrazinolysis, the resulting phthalimide derivative is transformed into 2-aminomethyl-1,4-dioxyspiro[4,5]decane, which is reacted with S-methylthiourea, giving the desired guanadrel.
Guanadrel can be synthesized when [[cyclohexanone]] undergoes ketalization by 3-chloro-1,2-propanediol, forming 2-chloromethyl-1,4-dioxyspiro[4,5]decane, which is further reacted with sodium phthalimide.<ref>W.R. Hardie, J.E. Aaron, {{Cite patent|FR|1522153}} (1968)</ref><ref>W.R. Hardie, J.E. Aaron, S. Afr. Pat. 67 06.328 (1968)</ref><ref>J.E. Aaron, W.R. Hardie, {{US Patent|3547951}} (1970)</ref> After alkaline hydrazinolysis, the resulting phthalimide derivative is transformed into 2-aminomethyl-1,4-dioxyspiro[4,5]decane, which is reacted with S-methylthiourea, giving the desired guanadrel.
:[[File:Guanadrel synthesis.png|800px|left|thumb|Guanadrel synthesis]]{{clear-left}}


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:drug]]
[[Category:Ketals]]
[[Category:Ketals]]
[[Category:Guanidines]]
[[Category:Guanidines]]
[[Category:Antihypertensive agents]]
[[Category:Antihypertensive agents]]

Latest revision as of 16:27, 20 August 2015

Template:Chembox new

WikiDoc Resources for Guanadrel

Articles

Most recent articles on Guanadrel

Most cited articles on Guanadrel

Review articles on Guanadrel

Articles on Guanadrel in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Guanadrel

Images of Guanadrel

Photos of Guanadrel

Podcasts & MP3s on Guanadrel

Videos on Guanadrel

Evidence Based Medicine

Cochrane Collaboration on Guanadrel

Bandolier on Guanadrel

TRIP on Guanadrel

Clinical Trials

Ongoing Trials on Guanadrel at Clinical Trials.gov

Trial results on Guanadrel

Clinical Trials on Guanadrel at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Guanadrel

NICE Guidance on Guanadrel

NHS PRODIGY Guidance

FDA on Guanadrel

CDC on Guanadrel

Books

Books on Guanadrel

News

Guanadrel in the news

Be alerted to news on Guanadrel

News trends on Guanadrel

Commentary

Blogs on Guanadrel

Definitions

Definitions of Guanadrel

Patient Resources / Community

Patient resources on Guanadrel

Discussion groups on Guanadrel

Patient Handouts on Guanadrel

Directions to Hospitals Treating Guanadrel

Risk calculators and risk factors for Guanadrel

Healthcare Provider Resources

Symptoms of Guanadrel

Causes & Risk Factors for Guanadrel

Diagnostic studies for Guanadrel

Treatment of Guanadrel

Continuing Medical Education (CME)

CME Programs on Guanadrel

International

Guanadrel en Espanol

Guanadrel en Francais

Business

Guanadrel in the Marketplace

Patents on Guanadrel

Experimental / Informatics

List of terms related to Guanadrel

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Guanadrel is an antihypertensive agent.[1] It is used in the form of its sulfate.

Mechanism of action

Guanadrel is a postganglionic adrenergic blocking agent. Uptake of guanadrel and storage in sympathetic neurons occurs via the norepinephrine pump; guanadrel slowly displaces norepinephrine from its storage in nerve endings and thereby blocks the release of norepinephrine normally produced by nerve stimulation. The reduction in neurotransmitter release in response to sympathetic nerve stimulation, as a result of catecholamine depletion, leads to reduced arteriolar vasoconstriction, especially the reflex increase in sympathetic tone that occurs with a change in position. Guanadrel is rapidly and well absorbed from gastrointestinal tract.[2]

In 1981 the JAMA reported guanadrel as an effective step II or step III treatment of hypertension.[3]

Chemistry

Guanadrel can be synthesized when cyclohexanone undergoes ketalization by 3-chloro-1,2-propanediol, forming 2-chloromethyl-1,4-dioxyspiro[4,5]decane, which is further reacted with sodium phthalimide.[4][5][6] After alkaline hydrazinolysis, the resulting phthalimide derivative is transformed into 2-aminomethyl-1,4-dioxyspiro[4,5]decane, which is reacted with S-methylthiourea, giving the desired guanadrel.

References

  1. Oren A, Rotmensch HH, Vlasses PH; et al. (1985). "A dose-titration trial of guanadrel as step-two therapy in essential hypertension". J Clin Pharmacol. 25 (5): 343–6. doi:10.1002/j.1552-4604.1985.tb02852.x. PMID 4031111.
  2. Guanadrel, from Pharmacogenetics Knowledge Base
  3. M. I. Dunn and J. L. Dunlap (1981). "Guanadrel. A new antihypertensive drug". JAMA. 245 (16): 1639–42. doi:10.1001/jama.1981.03310410017019. PMID 7206175.
  4. W.R. Hardie, J.E. Aaron, FR 1522153  (1968)
  5. W.R. Hardie, J.E. Aaron, S. Afr. Pat. 67 06.328 (1968)
  6. J.E. Aaron, W.R. Hardie, Template:US Patent (1970)